Genmab — Februar 2018
-
En ikke ukendt analytiker, der har talt med en KOL skriver: "He (the KOL) highlighted that Isatuximab from Sanofi probably has stronger inhibition of the ecto enzymatic activation versus other CD38 antibodies, which might lead to better efficacy in solid cancers, but that remains to be seen in the human clinical trials when they read out for Isatuximab and Darzalex respectively."
-
apropos solide...så har Incyte også fået øje på AXL og starter AXL/MER bispecifik op i klinik i løbet af 2018. http://adisinsight.springer.com/drugs/800051363
-
-
@Den Fattige: Du kan læse lidt om forventet kursuvikling efter et "Gaps Away" her: http://www.dstockmarket.com/breakaway-gaps.html
-
Om det er interessant, ved jeg ikke. Men mig bekendt er dette det eneste studie. Et ISS på MD Anderson https://www.clinicaltrials.gov/ct2/show/NCT03177460?term=daratumumab+prostate&rank=1
-
De har jo så også det andet studie i prostata som er aflyst. Nogen som kender begrundelsen. ?? https://www.clinicaltrials.gov/ct2/show?term=daratumumab+prostate&rank=2
-
Noget kunne tyde på, at cd38 spiller en rolle som biomarkør for aggressiv prostata cancer. Men det er vel ikke det samme, som at det kan bruges behandlingsmæssigt? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814231/
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind